RTP Mobile Logo
Select Publications

Barlesi F et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Proc ELCC 2019;Abstract 109O.

Camidge DR et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018;379(21):2027-39. Abstract

Cappuzzo F et al. IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Proc ESMO 2018;Abstract LBA53.

Chung HC et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. Proc AACR 2019;Abstract CT073.

De Braud FGM et al. Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Proc ESMO 2019;Abstract 1488PD.

Doebele R et al. Entrectinib in NTRK-fusion positive NSCLC: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Proc AACR 2019;Abstract CT131.

Drilon A et al. Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. WCLC 2019;Abstract PL02.08.

Drilon A et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378(8):731-9. Abstract

Gainor JF et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). ASCO 2019;Abstract 9008.

Hellmann MD et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019;[Epub ahead of print]. Abstract

Hellmann MD et al. Nivolumab +/- ipilimumab in advanced small cell lung cancer: First report of a randomized cohort from CheckMate 032. ASCO 2017;Abstract 8503.

Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract

Jänne PA et al. Osimertinib plus platinum/pemetrexed in newly-diagnosed advanced EGFRm-positive NSCLC; The phase 3 FLAURA2 study. WCLC 2019;Abstract OA07.01.

Mok T et al. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev 2017;55:181-9. Abstract

Nakagawa K et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;[Epub ahead of print]. Abstract

Paik PK et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. ASCO 2019;Abstract 9005.

Paz-Ares L et al. Entrectinib in NTRK-fusion positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Proc ELCC 2019;Abstract 1130.

Paz-Ares L et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: Results from the CASPIAN study. WCLC 2019;Abstract PL02.11.

Paz-Ares L et al. Pembrolizumab + chemotherapy in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407. Proc ESMO 2019;Abstract LBA82.

Peters S et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377(9):829-38. Abstract

Ramalingam SS et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Proc ESMO 2019;Abstract LBA5_PR.

Ready N et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 2019;14(2):237-44. Abstract

Reck M et al. IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Proc ELCC 2019;Abstract 104O.

Reinmuth N et al. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. Proc ESMO 2019;Abstract LBA4.

Socinski MA et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378(24):2288-301. Abstract

Solomon BJ et al. Efficacy of lorlatinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. Proc ESMO 2018;Abstract 1380PD.

Soria JC et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomized, open-label, phase 3 study. Lancet 2017;389(10072):917-29. Abstract

Spigel D et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. Proc ESMO 2019;Abstract LBA78.

Tran PN, Klempner SJ. Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne) 2016;3:65. Abstract

West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower10): A multicenter, randomized, open-label, phase 3 trial. Lancet Oncol 2019;20(7):924-37. Abstract

Wolf J et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. ASCO 2019;Abstract 9004.

Zhang I et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015;16:e510-21. Abstract